Patient characteristics for phase 1/2 cohorts
| Variable . | Data . |
|---|---|
| Total treated | 36 (100) |
| Age, median (range), y | 60 (17-72) |
| Time to HCT from AML diagnosis, median (range), d | 142 (55-2051) |
| Sex | |
| Female | 14 (39) |
| Male | 22 (61) |
| HCT-CI, median (range) | 3 (0-7) |
| HCT-CI ≥ 3 | 23 (64) |
| HCT-CI < 3 | 13 (36) |
| Disease status at HCT | |
| Not in remission | 35 (97) |
| Remission | 1 (3) |
| % Blasts at HCT | |
| ≥5% | 20 (56) |
| <5%* | 16 (34) |
| Cytogenetic risk | |
| Poor | 18 (50) |
| Intermediate | 17 (47) |
| Unknown | 1 (3) |
| FLT3-ITD/NPM1 mutation | |
| +/+ | 1 (3) |
| +/− | 2 (6) |
| −/+ | 2 (6) |
| −/− | 17 (47) |
| Unknown | 14 (38) |
| Disease risk score32 | |
| ≥3 | 21 (58) |
| 2 | 12 (33) |
| 1 | 3 (9) |
| Conditioning regimen | |
| CloBu | 17 (47) |
| FluBu | 17 (47) |
| FluTBI | 2 (6) |
| HLA match/donor type | |
| Matched/unrelated | 20 (56) |
| Matched/related | 14 (38) |
| Haploidentical/related | 2 (6) |
| Donor source | |
| PBMCs | 31 (86) |
| Bone marrow | 5 (14) |
| Variable . | Data . |
|---|---|
| Total treated | 36 (100) |
| Age, median (range), y | 60 (17-72) |
| Time to HCT from AML diagnosis, median (range), d | 142 (55-2051) |
| Sex | |
| Female | 14 (39) |
| Male | 22 (61) |
| HCT-CI, median (range) | 3 (0-7) |
| HCT-CI ≥ 3 | 23 (64) |
| HCT-CI < 3 | 13 (36) |
| Disease status at HCT | |
| Not in remission | 35 (97) |
| Remission | 1 (3) |
| % Blasts at HCT | |
| ≥5% | 20 (56) |
| <5%* | 16 (34) |
| Cytogenetic risk | |
| Poor | 18 (50) |
| Intermediate | 17 (47) |
| Unknown | 1 (3) |
| FLT3-ITD/NPM1 mutation | |
| +/+ | 1 (3) |
| +/− | 2 (6) |
| −/+ | 2 (6) |
| −/− | 17 (47) |
| Unknown | 14 (38) |
| Disease risk score32 | |
| ≥3 | 21 (58) |
| 2 | 12 (33) |
| 1 | 3 (9) |
| Conditioning regimen | |
| CloBu | 17 (47) |
| FluBu | 17 (47) |
| FluTBI | 2 (6) |
| HLA match/donor type | |
| Matched/unrelated | 20 (56) |
| Matched/related | 14 (38) |
| Haploidentical/related | 2 (6) |
| Donor source | |
| PBMCs | 31 (86) |
| Bone marrow | 5 (14) |
CloBu, Clofarabine + Busulfan; FluBu, Fludarabine + Busulfan; FluTBI, Fludarabine + Total Body Irradiation. *Persistence of AML by cytogenetics (n = 10), flow cytometry (n = 4), myeloid sarcoma (n = 1), or not detected (n = 1).